Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Shweta Joshi

    TitleAssistant Project Scientist
    SchoolUniversity of California, San Diego
    DepartmentPediatrics
    Address9500 Gilman Drive #0815
    CA La Jolla 92093
    Phone858-246-1611
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Joshi S, Singh AR, Wong SS, Zulcic M, Jiang M, Pardo A, Selman M, Hagood JS, Durden DL. Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype. PLoS One. 2017; 12(8):e0182851. PMID: 28817691.
        View in: PubMed
      2. Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, Durden DL, Kutateladze TG. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci U S A. 2017 Feb 14; 114(7):E1072-E1080. PMID: 28137841.
        View in: PubMed
      3. Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, Durden DL. Association of high microvessel avß3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget. 2017 Aug 08; 8(32):52193-52210. PMID: 28881723.
        View in: PubMed
      4. Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther. 2016 Nov; 15(11):2553-2562. PMID: 27496136.
        View in: PubMed
      5. Singh AR, Joshi S, Zulcic M, Alcaraz M, Garlich JR, Morales GA, Cho YJ, Bao L, Levy ML, Newbury R, Malicki D, Messer K, Crawford J, Durden DL. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS One. 2016; 11(3):e0150836. PMID: 26938241; PMCID: PMC4777592.
      6. Bhat V, Olmer M, Joshi S, Durden DL, Cramer TJ, Barnes RF, Ball ST, Hughes TH, Silva M, Luck JV, Moore RE, Mosnier LO, von Drygalski A. Vascular remodeling underlies rebleeding in hemophilic arthropathy. Am J Hematol. 2015 Nov; 90(11):1027-35. PMID: 26257191; PMCID: PMC4618067 [Available on 11/01/16].
      7. Joshi S, Singh AR, Durden DL. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. Cancer Chemother Pharmacol. 2015 Mar; 75(3):595-608. PMID: 25578041.
        View in: PubMed
      8. Singh AR, Joshi S, George E, Durden DL. Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12)?V-Ha-Ras transgenic mouse glioma model. Cancer Cell Int. 2014; 14(1):105. PMID: 25425962; PMCID: PMC4243316.
      9. Joshi S, Singh AR, Zulcic M, Durden DL. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1a and HIF2a stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res. 2014 Oct; 12(10):1520-31. PMID: 25103499.
        View in: PubMed
      10. Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden DL. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol. 2014 Aug; 36(6):451-7. PMID: 24309609; PMCID: PMC4356196.
      11. Joshi S, Singh AR, Durden DL. MDM2 regulates hypoxic hypoxia-inducible factor 1a stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. J Biol Chem. 2014 Aug 15; 289(33):22785-97. PMID: 24982421; PMCID: PMC4132784.
      12. Singh AR, Peirce SK, Joshi S, Durden DL. PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. Exp Cell Res. 2014 Sep 10; 327(1):78-90. PMID: 24881819.
        View in: PubMed
      13. Joshi S, Singh AR, Zulcic M, Durden DL. A PKC-SHP1 signaling axis desensitizes Fc? receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates Fc?R mediated phagocytosis. BMC Immunol. 2014 May 07; 15:18. PMID: 24886428; PMCID: PMC4017086.
      14. Joshi S, Singh AR, Zulcic M, Bao L, Messer K, Ideker T, Dutkowski J, Durden DL. Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. PLoS One. 2014; 9(4):e95893. PMID: 24770346; PMCID: PMC4000195.
      15. Muh CR, Joshi S, Singh AR, Kesari S, Durden DL, Makale MT. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1a suppression. J Neurooncol. 2014 Jan; 116(1):89-97. PMID: 24162827; PMCID: PMC3896301.
      16. Singh AR, Joshi S, Arya R, Kayastha AM, Saxena JK. Guanidine hydrochloride and urea-induced unfolding of Brugia malayi hexokinase. Eur Biophys J. 2010 Jan; 39(2):289-97. PMID: 19756573.
        View in: PubMed
      17. Singh AR, Joshi S, Arya R, Kayastha AM, Srivastava KK, Tripathi LM, Saxena JK. Molecular cloning and characterization of Brugia malayi hexokinase. Parasitol Int. 2008 Sep; 57(3):354-61. PMID: 18499511.
        View in: PubMed
      18. Joshi S, Singh AR, Kumar A, Misra PC, Siddiqi MI, Saxena JK. Molecular cloning and characterization of Plasmodium falciparum transketolase. Mol Biochem Parasitol. 2008 Jul; 160(1):32-41. PMID: 18456347.
        View in: PubMed
      19. Singh SK, Joshi S, Singh AR, Saxena JK, Pandey DS. DNA binding and topoisomerase II inhibitory activity of water-soluble ruthenium(II) and rhodium(III) complexes. Inorg Chem. 2007 Dec 10; 46(25):10869-76. PMID: 18001110.
        View in: PubMed